$NRXS
Neuraxis, INC Stock $nrxs

$nrxs Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223033460 Filed on September 22, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q4
Revenue	$477.5K	$646.0K	$613.1K
YoY Change		-5.36%	30.44%
Cost Of Revenue	$67.29K	$67.81K	$75.21K
YoY Change	-69.67%	-14.17%	7.44%
Gross Profit	$410.2K	$578.2K	$537.9K
YoY Change	-77.83%	-4.2%	34.47%
Gross Profit Margin	85.91%	89.5%	87.73%
Selling, General & Admin	$3.388M	$1.586M	$1.443M
YoY Change	-17.21%	25.92%	21.24%
% of Gross Profit	825.89%	274.29%	268.23%
Research & Development	$44.95K	$109.8K	$81.37K
YoY Change	-68.84%	703.43%	62.74%
% of Gross Profit	10.96%	18.99%	15.13%
Depreciation & Amortization	$7.609K	$7.589K	$12.08K
YoY Change	-69.62%	-3.08%	20.8%
% of Gross Profit	1.86%	1.31%	2.25%
Operating Expenses	$3.433M	$1.696M	$1.524M
YoY Change	-18.96%	33.19%	22.91%
Operating Profit	-$3.022M	-$1.118M	-$986.2K
YoY Change	26.67%	66.9%	17.41%
Interest Expense	$102.6K	$194.7K	-$223.7K
YoY Change	-106.03%	465.14%	459.2%
% of Operating Profit
Other Income/Expense, Net	-$1.882M	-$1.118M	$1.196M
YoY Change	177.91%	32.01%	3887.6%
Pretax Income	-$4.900M	-$2.240M	-$13.63K
YoY Change	2.8%	47.37%	-98.4%
Income Tax
% Of Pretax Income
Net Earnings	-$4.904M	-$2.236M	-$206.4K
YoY Change	-8.13%	47.42%	-80.34%
Net Earnings / Revenue	-1027.18%	-346.06%	-33.67%
Basic Earnings Per Share	-$1.35	-$1.21
Diluted Earnings Per Share	-$1.35	-$1.21	-$0.03
COMMON SHARES
Basic Shares Outstanding	4.981M shares	2.003M shares
Diluted Shares Outstanding	3.626M shares	2.003M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$760.0K	$50.00K	$253.7K
YoY Change	9618.67%
Cash & Equivalents	$761.2K	$51.44K	$253.7K
Short-Term Investments
Other Short-Term Assets	$40.00K	$20.00K	$730.00
YoY Change	147.68%
Inventory	$34.53K	$44.21K	$48.13K
Prepaid Expenses
Receivables	$132.4K	$237.2K	$174.4K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$966.9K	$354.1K	$477.0K
YoY Change	140.79%
LONG-TERM ASSETS
Property, Plant & Equipment	$80.33K	$85.26K	$189.4K
YoY Change	-60.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$940.0K	$736.7K
YoY Change	-100.0%
Total Long-Term Assets	$269.1K	$1.186M	$1.004M
YoY Change	-71.08%
TOTAL ASSETS
Total Short-Term Assets	$966.9K	$354.1K	$477.0K
Total Long-Term Assets	$269.1K	$1.186M	$1.004M
Total Assets	$1.236M	$1.540M	$1.481M
YoY Change	-7.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$566.6K	$2.438M	$1.592M
YoY Change	-60.93%
Accrued Expenses	$280.1K	$1.174M	$867.5K
YoY Change	-67.04%
Deferred Revenue
YoY Change
Short-Term Debt	$194.0K	$1.500M	$286.4K
YoY Change	122.94%
Long-Term Debt Due	$190.0K	$250.0K	$202.8K
YoY Change	-1.09%
Total Short-Term Liabilities	$2.258M	$11.43M	$6.978M
YoY Change	-66.59%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$40.00K	$0.00
YoY Change	-100.0%
Other Long-Term Liabilities	$40.00K	$50.00K	$76.20K
YoY Change	-52.69%
Total Long-Term Liabilities	$39.35K	$90.43K	$76.20K
YoY Change	-71.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.258M	$11.43M	$6.978M
Total Long-Term Liabilities	$39.35K	$90.43K	$76.20K
Total Liabilities	$2.297M	$11.52M	$7.054M
YoY Change	-66.68%
SHAREHOLDERS EQUITY
Retained Earnings	-$43.24M	-$38.34M	-$33.93M
YoY Change
Common Stock	$5.149K	$1.963K	$1.963K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.100M	-$10.00M	-$5.574M
YoY Change
Total Liabilities & Shareholders Equity	$1.236M	$1.540M	$1.481M
YoY Change	-7.21%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q4
OPERATING ACTIVITIES
Net Income	-$4.904M	-$2.236M	-$206.4K
YoY Change	-8.13%	47.42%	-80.34%
Depreciation, Depletion And Amortization	$7.609K	$7.589K	$12.08K
YoY Change	-69.62%	-3.08%	20.8%
Cash From Operating Activities	-$2.810M	-$630.0K	-$214.3K
YoY Change	34.86%	-35.71%	12.79%
INVESTING ACTIVITIES
Capital Expenditures	$50.00K	$0.00	$49.82K
YoY Change	338.98%	-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$50.00K	$0.00	-$49.82K
YoY Change	338.98%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$6.600M		$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.570M	640.0K	510.0K
YoY Change	100.33%	-36.63%	112.5%
NET CHANGE
Cash From Operating Activities	-2.810M	-630.0K	-214.3K
Cash From Investing Activities	-50.00K	0.000	-49.82K
Cash From Financing Activities	3.570M	640.0K	510.0K
Net Change In Cash	710.0K	10.00K	245.9K
YoY Change	-326.81%	-150.0%	391.76%
FREE CASH FLOW
Cash From Operating Activities	-$2.810M	-$630.0K	-$214.3K
Capital Expenditures	$50.00K	$0.00	$49.82K
Free Cash Flow	-$2.860M	-$630.0K	-$264.1K
YoY Change	36.51%	-38.83%	39.02%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001933567
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable		usd
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q2	NRXS	Financing Charges FinancingCharges		usd
CY2022Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2022Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023Q2	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2023Q2	us-gaap	Interest Receivable Current InterestReceivableCurrent		usd
CY2023Q2	NRXS	Interest Income Current InterestIncomeCurrent		usd
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2022Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent		usd
CY2022Q4	NRXS	Interest Income Current InterestIncomeCurrent		usd
	us-gaap	Interest Paid InterestPaid		usd
CY2022	us-gaap	Interest Paid InterestPaid		usd
CY2022Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent		usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41775
	dei	Entity Registrant Name EntityRegistrantName	NEURAXIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	45-5079684
	dei	Entity Address Address Line1 EntityAddressAddressLine1	11550 N. Meridian Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 325
	dei	Entity Address City Or Town EntityAddressCityOrTown	Carmel
	dei	Entity Address State Or Province EntityAddressStateOrProvince	IN
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	46032
	dei	City Area Code CityAreaCode	(812)
	dei	Local Phone Number LocalPhoneNumber	689-0791
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	NRXS
	dei	Security Exchange Name SecurityExchangeName	NYSEAMER
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4981349	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	51440	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	253699	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	237170	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174399	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	44205	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	48133	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21333	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	726	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	354148	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	476957	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	417912	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	332651	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85261	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2023Q2	us-gaap	Deferred Costs DeferredCosts	941143	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	736736	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85823	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	73316	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023Q2	us-gaap	Assets Assets	1539691	usd
CY2022Q4	us-gaap	Assets Assets	1480644	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2438117	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1592116	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1174381	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	41261	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	33395	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	4421424	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	3327213	usd
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1217465	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	228342	usd
CY2023Q2	us-gaap	Deposits Deposits	61317	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	2275029	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1735700	usd
CY2023Q2	NRXS	Warrant Liabilities WarrantLiabilities	3916884	usd
CY2022Q4	NRXS	Warrant Liabilities WarrantLiabilities	2234384	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11431894	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6978058	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51635	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	38797	usd
CY2023Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	90432	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	76199	usd
CY2023Q2	us-gaap	Liabilities Liabilities	11522326	usd
CY2022Q4	us-gaap	Liabilities Liabilities	7054257	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1963322	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	1963322	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1963322	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1963322	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	1963	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1963	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28355230	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	28355230	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-38340450	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33931428	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9982635	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1539691	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1480644	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	646021	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	682581	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1451131	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1452848	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	67813	usd
CY2022Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	79009	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	163713	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	154209	usd
CY2023Q2	us-gaap	Gross Profit GrossProfit	578208	usd
CY2022Q2	us-gaap	Gross Profit GrossProfit	603572	usd
	us-gaap	Gross Profit GrossProfit	1287418	usd
	us-gaap	Gross Profit GrossProfit	1298639	usd
CY2023Q2	us-gaap	Selling Expense SellingExpense	78791	usd
CY2022Q2	us-gaap	Selling Expense SellingExpense	127424	usd
	us-gaap	Selling Expense SellingExpense	186723	usd
	us-gaap	Selling Expense SellingExpense	263304	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	109789	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13665	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	126586	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	58063	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1507169	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1132065	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2987923	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2160161	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1117541	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-669582	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2013814	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1182889	usd
CY2022Q2	NRXS	Financing Charges FinancingCharges	872763	usd
	NRXS	Financing Charges FinancingCharges	2772	usd
	NRXS	Financing Charges FinancingCharges	872763	usd
CY2023Q2	us-gaap	Interest Expense InterestExpense	194690	usd
CY2022Q2	us-gaap	Interest Expense InterestExpense	34450	usd
	us-gaap	Interest Expense InterestExpense	356378	usd
	us-gaap	Interest Expense InterestExpense	60550	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	36050	usd
CY2022Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-61520	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-198757	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	569561	usd
CY2023Q2	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	860	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	192157	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	887937	usd
CY2022Q2	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12944	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3550592	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12944	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1129498	usd
CY2023Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	2	usd
CY2022Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11689	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1552	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	11956	usd
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	258	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	7430	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1118073	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-846948	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2395208	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1503862	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2235614	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1516530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4409022	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2686751	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1970054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1970054	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1970054	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1970054	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-825660	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11994	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-1170221	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-1983887	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12127	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1048	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1516530	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-3487242	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-5573613	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2173408	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7747021	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-7747021	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2235614	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9982635	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-9982635	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4409022	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2686751	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3550592	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12944	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20060	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16695	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3927	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	29580	usd
	NRXS	Noncash Lease Expense NoncashLeaseExpense	15559	usd
	NRXS	Noncash Lease Expense NoncashLeaseExpense	13296	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	24121	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1129498	usd
	NRXS	Finance Charges FinanceCharges	2772	usd
	NRXS	Finance Charges FinanceCharges	872763	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	192157	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-198757	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	569561	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	66698	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	131764	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3928	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	13616	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	20607	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	138	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	846001	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-118561	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	340318	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	266486	usd
	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	2143	usd
	NRXS	Increase Decrease In Customer Deposit IncreaseDecreaseInCustomerDeposit	-12720	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-16698	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-13791	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1248137	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1171895	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12067	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	49815	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13067	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-49815	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2724479	usd
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	86453	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	159831	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3828000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1087500	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	204407	usd
	us-gaap	Payments For Repurchase Of Initial Public Offering PaymentsForRepurchaseOfInitialPublicOffering	26549	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1058945	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	974498	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-202259	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-247212	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	253699	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	320858	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	51440	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	73646	usd
	us-gaap	Interest Paid Net InterestPaidNet	57202	usd
	us-gaap	Interest Paid Net InterestPaidNet	55550	usd
	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	1881257	usd
	NRXS	Fair Value Of Warrant Liabilities Of Warrants From Convertible Notes FairValueOfWarrantLiabilitiesOfWarrantsFromConvertibleNotes	884118	usd
	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	1860984	usd
	NRXS	Fair Value Of Derivative Liabilities Of Conversion Feature From Convertible Notes FairValueOfDerivativeLiabilitiesOfConversionFeatureFromConvertibleNotes	1075098	usd
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	4-for-1 stock split
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2700000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	13400000	shares
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-2 reverse stock split
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2190102	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zkCneRLmRVgd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86F_zq28BEpOcM36">Use of Estimates and Critical Accounting Estimates and Assumptions</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These significant accounting estimates or assumptions bear the risk of change due to the fact that there are uncertainties attached to these estimates or assumptions, and certain estimates or assumptions are difficult to measure or value.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management bases its estimates on historical experience and on various assumptions that are believed to be reasonable in relation to the financial statements taken as a whole under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management regularly evaluates the key factors and assumptions used to develop the estimates utilizing currently available information, changes in facts and circumstances, historical experience, and reasonable assumptions. After such evaluations, if deemed appropriate, those estimates are adjusted accordingly. The Company uses estimates in accounting for, among other items, revenue recognition, allowance for doubtful accounts, stock-based compensation, income tax provisions, excess and obsolete inventory reserve, and impairment of intellectual property. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p>
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	15989	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	31275	usd
CY2023Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	7714	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	3927	usd
CY2022Q2	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	21307	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	29580	usd
CY2023Q2	us-gaap	Deposits Deposits	61317	usd
CY2022Q4	us-gaap	Deposits Deposits	59174	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10026	usd
CY2023Q2	us-gaap	Deferred Costs DeferredCosts	941143	usd
CY2022Q4	us-gaap	Deferred Costs DeferredCosts	736736	usd
CY2023Q2	us-gaap	Depreciation Depreciation	7589	usd
	us-gaap	Depreciation Depreciation	14817	usd
CY2022Q2	us-gaap	Depreciation Depreciation	7830	usd
	us-gaap	Depreciation Depreciation	15725	usd
CY2022Q3	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	40000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2621	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5243	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	970	usd
CY2023Q2	us-gaap	Advertising Expense AdvertisingExpense	24986	usd
	us-gaap	Advertising Expense AdvertisingExpense	32986	usd
CY2022Q2	us-gaap	Advertising Expense AdvertisingExpense	3300	usd
	us-gaap	Advertising Expense AdvertisingExpense	11600	usd
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	40000	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2569405	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4994069	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3053522	shares
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2235614	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-1516530	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4409022	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2686751	usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-190699	usd
CY2022Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-190699	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-379303	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-379303	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-2426313	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1707229	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4788325	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3066054	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1970054	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1970054	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2003322	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2003322	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1970054	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1970054	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.21
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.21
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.87
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.87
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.39
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.39
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.56
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.56
CY2023Q2	us-gaap	Revenues Revenues	646021	usd
CY2022Q2	us-gaap	Revenues Revenues	682581	usd
	us-gaap	Revenues Revenues	1451131	usd
	us-gaap	Revenues Revenues	1452848	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	115301	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	174399	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2022Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	237170	usd
CY2023Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	0	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2621	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	485	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5243	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	970	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	22904	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84C_eus-gaap--ConcentrationRiskCreditRisk_zXunPVXF1Pg7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86E_zRYNWfCLFem4">Concentrations of Credit Risk</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s business activity consists of the sale of medical neuromodulation devices to doctors, clinics, and hospitals across the country.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receivables consist of unsecured amounts due from customers. As of June 30, 2023, accounts receivable from two customers with balances due in excess of <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zqsilPm7tokb" title="Risk percentage">10</span>% of total accounts receivable were approximately <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3xXxmGF46r9" title="Risk percentage">13</span>%, and <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztuqoixpYtl6" title="Risk percentage">13</span>%, respectively. As of December 31, 2022, accounts receivable from three customers with balances due in excess of <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueProductLineMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--RevenueFromRightsConcentrationRiskMember_zCZhyzr8WwEj" title="Risk percentage">10</span>% of total accounts receivable was<span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z04xnJIuHCMh" title="Risk percentage"> 23</span>%, <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zeAeETMBl3F" title="Risk percentage">15</span>%, and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zsKT1NGY1tw5" title="Risk percentage">12</span>%, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.2pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below sets forth the Company’s customers that accounted for greater than 10% of its revenues for the three months ended June 30, 2023 and 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89F_eus-gaap--ContractWithCustomerAssetAllowanceForCreditLossTableTextBlock_zQf9rzUgg0fk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B3_zPuhhtEPQPn1">Schedule of Customers Accounted Revenues</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2023</b></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><b>2022</b></td><td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Percentage of Sales</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2" style="text-align: center"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; text-align: left">Hospital A</td><td style="width: 2%; font-weight: bold"> </td> <td style="width: 1%; font-weight: bold; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z11lm2qav2l5" style="width: 16%; font-weight: bold; text-align: right" title="Revenue">95,200</td><td style="width: 1%; font-weight: bold; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 16%; text-align: right"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zKJpv7siYu08" title="Risk percentage">15</span></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zhGpaL3Vn5il" style="width: 16%; text-align: right" title="Revenue">131,700</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td><td style="width: 16%; text-align: right"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxen58xAJuk5" title="Risk percentage">19</span></td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Hospital B</td><td style="font-weight: bold"> </td> <td style="font-weight: bold; text-align: left"> </td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zyFJJusvoqza" style="font-weight: bold; text-align: right" title="Revenue">8,900</td><td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: right"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6iUoVBddlO7" title="Risk percentage">1</span></td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zoMLQqCcxiKh" style="text-align: right" title="Revenue">120,800</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center"> </td><td style="text-align: right"><span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUz6PEhXgVY" title="Risk percentage">17</span></td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Hospital C</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left"> </td><td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zgn0C3zUafgh" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">138,400</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_904_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z89VJ3OCtP08" title="Risk percentage">21</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z3j4ztkPDk63" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">114,730</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zNiYeWKpgU12" title="Risk percentage">16</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">$</td><td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zylcF4mZCzje" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right" title="Revenue">242,500</td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zmtRRol9X9J6" title="Risk percentage">37</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zIRMYtIoYGfa" style="border-bottom: Black 1.5pt solid; text-align: right" title="Revenue">367,230</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: center"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220401__20220630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUipaMLb1TR4" title="Risk percentage">52</span></td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The table below sets forth the Company’s customers that accounted for greater than 10% of its revenues for the six months ended June 30, 2023 and 2022, respectively. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2023</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage of Sales</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>2022</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Percentage of Sales</b></span></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 20%"><span style="font-size: 10pt">Hospital A</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zS11Bip3aE54" style="width: 16%; text-align: right" title="Revenue"><span style="font-size: 10pt"><b>185,550</b></span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zAAqQh9BP5sf" title="Risk percentage">13</span></span></td> <td style="width: 1%"><span style="font-size: 10pt">%</span></td> <td style="width: 2%"> </td> <td style="width: 1%"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zo7hhR6maytd" style="width: 16%; text-align: right" title="Revenue"><span style="font-size: 10pt">370,000</span></td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%; text-align: center"> </td> <td style="width: 16%; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalAMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_ztCorfaXehrj" title="Risk percentage">25</span></span></td> <td style="width: 1%"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><span style="font-size: 10pt">Hospital B</span></td> <td> </td> <td> </td> <td id="xdx_98E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zMNbq0mIq9ra" style="text-align: right" title="Revenue"><span style="font-size: 10pt"><b>291,420</b></span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7BcCd710Ega" title="Risk percentage">20</span></span></td> <td><span style="font-size: 10pt">%</span></td> <td> </td> <td> </td> <td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zbYplSRcFhC5" style="text-align: right" title="Revenue"><span style="font-size: 10pt">243,000</span></td> <td> </td> <td> </td> <td style="text-align: center"> </td> <td style="text-align: right"><span style="font-size: 10pt"><span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalBMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zXNeAWK3Qyl7" title="Risk percentage">16</span></span></td> <td><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Hospital C</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_981_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zZBVYyMjGuj6" style="border-bottom: black 1.5pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt"><b>131,100</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zATPGAkuTejc" title="Risk percentage">9</span></span></td> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td id="xdx_982_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zaKlaoXzAiR3" style="border-bottom: black 1.5pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">188,205</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalCMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zQrrDtd2fFyg" title="Risk percentage">13</span></span></td> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt"><b>$</b></span></td> <td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zCtIvZZRcrPb" style="border-bottom: black 1.5pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt"><b>608,070</b></span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z5l41NVzI0fd" title="Risk percentage">42</span></span></td> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td> <td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zspcrSuUxSzh" style="border-bottom: black 1.5pt solid; text-align: right" title="Revenue"><span style="font-size: 10pt">801,205</span></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20220630__srt--MajorCustomersAxis__custom--HospitalMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zGITkkB6C69" title="Risk percentage">54</span></span></td> <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A5_zpPlb86ClXx3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 5.15pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">From time to time, the Company’s bank balances may exceed the FDIC limit of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_iI_c20230630_zG8FGPWxeM33" title="Cash, FDIC insured amount">250,000</span>; however, management does not feel that this has a material impact on the financial condition. At June 30, 2023 and December 31, 2022, the Company’s uninsured cash balances totaled $<span id="xdx_900_eus-gaap--CashUninsuredAmount_iI_c20230630_zsrnsQrcOK5c" title="Cash, uninsured amount"><span id="xdx_90C_eus-gaap--CashUninsuredAmount_iI_c20221231_zuaDDVASp5kd" title="Cash, uninsured amount">0</span></span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.8pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-10000000.0	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	1500000	usd
CY2023Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4421424	usd
CY2023Q2	us-gaap	Cash Cash	51000	usd
CY2023Q2	NRXS	Working Capital Deficit WorkingCapitalDeficit	11000000.0	usd
CY2023Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6600000	usd
CY2023Q2	NRXS	Allowance For Interest Receivable Current AllowanceForInterestReceivableCurrent	1128989	usd
CY2023Q2	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	1012800	usd
CY2023Q2	NRXS	Interest Receivable Gross Current InterestReceivableGrossCurrent	116188	usd
CY2023Q2	NRXS	Interest Income Gross Current InterestIncomeGrossCurrent	22182	usd
CY2022Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	1012800	usd
CY2022Q4	NRXS	Interest Receivable Gross Current InterestReceivableGrossCurrent	94007	usd
CY2022Q4	NRXS	Interest Income Gross Current InterestIncomeGrossCurrent	23046	usd
CY2023Q2	us-gaap	Loans Payable LoansPayable	58051	usd
CY2023Q2	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	102643	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	58051	usd
CY2022Q4	NRXS	Interest And Service Fee Accrued InterestAndServiceFeeAccrued	98290	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	417912	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	405845	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	332651	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	317834	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	85261	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	88011	usd
CY2023Q2	us-gaap	Depreciation Depreciation	7589	usd
CY2022Q2	us-gaap	Depreciation Depreciation	7830	usd
	us-gaap	Depreciation Depreciation	14817	usd
	us-gaap	Depreciation Depreciation	15725	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	93279	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	92278	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19963	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14720	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	73316	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	77558	usd
CY2023Q2	NRXS	Accrued Wages Current AccruedWagesCurrent	561772	usd
CY2022Q4	NRXS	Accrued Wages Current AccruedWagesCurrent	523003	usd
CY2023Q2	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	26286	usd
CY2022Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	16555	usd
CY2023Q2	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	89199	usd
CY2023Q2	NRXS	Capital Raise Fees CapitalRaiseFees	-3250	usd
CY2022Q4	NRXS	Capital Raise Fees CapitalRaiseFees	88259	usd
CY2023Q2	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	866	usd
CY2022Q4	us-gaap	Accrual For Taxes Other Than Income Taxes Current AccrualForTaxesOtherThanIncomeTaxesCurrent	777	usd
CY2023Q2	us-gaap	Interest Payable Current InterestPayableCurrent	463512	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	173826	usd
CY2023Q2	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent	35996	usd
CY2022Q4	NRXS	Related Party Interest Payable Current RelatedPartyInterestPayableCurrent	31642	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1174381	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	834062	usd
CY2023Q2	us-gaap	Debt Instrument Annual Principal Payment DebtInstrumentAnnualPrincipalPayment	87524	usd
CY2023Q2	us-gaap	Embedded Derivative Fair Value Of Embedded Derivative Liability EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability	4316047	usd
CY2023Q2	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	4693703	usd
CY2022Q4	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	2324988	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3649528	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	92896	usd
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	4-for-1 stock split
	us-gaap	Lessee Operating Lease Description LesseeOperatingLeaseDescription	Two of the leases in Versailles started January 1, 2017. Both have an initial term of five years with an option for an additional five-year term. The monthly lease payments for these leases are $550 and $1,600 with a 3% per annum increase starting with the optional five-year term. The lease in Carmel started March 1, 2016. The initial term is five years and three months with an option for an additional three-year term. The monthly lease payment started at $1,472 with an annual increase of approximately 2.7%. On December 16, 2020, the Company entered into an amendment of the Carmel lease that extended the initial term by two years
	us-gaap	Operating Lease Payments OperatingLeasePayments	550	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	1600	usd
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.03	pure
	us-gaap	Operating Lease Cost OperatingLeaseCost	1472	usd
CY2023Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.027	pure
	us-gaap	Operating Lease Expense OperatingLeaseExpense	23704	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	47571	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	85823	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	101382	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	41261	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	33395	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	51635	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	76199	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	92896	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	109594	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y9M
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.150	pure
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	22268	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	36302	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	28192	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	29038	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	115800	usd
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	2700000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	10800000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	13400000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	2-for-1 reverse stock split
CY2023Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1039680	shares
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1120000	shares
	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	80	pure
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M8D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M8D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1319394	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y2M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.94
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	1319394	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P6Y2M12D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	6.94
CY2023Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0	usd
	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.03	pure
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	9731	usd
	us-gaap	Defined Contribution Plan Administrative Expenses DefinedContributionPlanAdministrativeExpenses	8554	usd
CY2019Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	5000000	usd
CY2022Q3	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	75000	usd
	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	117122	usd
	us-gaap	Health Care Organization Stop Loss Insurance Premium Expense HealthCareOrganizationStopLossInsurancePremiumExpense	90752	usd
	NRXS	Health Care Organization Stop Loss Insurance Premium Percentage HealthCareOrganizationStopLossInsurancePremiumPercentage	0.485	pure
CY2022Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	1244228	shares

Files In Submission

Name	View Source	Status
nrxs-20230630_cal.xml	Edgar Link	unprocessable
0001493152-23-033460-index-headers.html	Edgar Link	pending
0001493152-23-033460-index.html	Edgar Link	pending
0001493152-23-033460.txt	Edgar Link	pending
0001493152-23-033460-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
nrxs-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
nrxs-20230630_lab.xml	Edgar Link	unprocessable
nrxs-20230630_def.xml	Edgar Link	unprocessable
nrxs-20230630_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NRXS
Neuraxis, INC Stock $nrxs

2023 Q3 Form 10-Q Financial Statement

#000149315223033460 Filed on September 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS Neuraxis, INC Stock $nrxs

2023 Q3 Form 10-Q Financial Statement

#000149315223033460 Filed on September 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NRXS
Neuraxis, INC Stock $nrxs